ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1443

Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features

Eleni Papachristodoulou, Daniel Magliulo and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA

Meeting: ACR Convergence 2022

Keywords: Cohort Study, prognostic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with SLE often develop lymphadenopathy (LAD), regarded as a relatively common manifestation of the disease. Its clinical significance has not yet been elucidated. We examined whether the presence of LAD and its different phenotypes is associated with other SLE clinical and laboratory manifestations.

Methods: We conducted a cross-sectional study of patients enrolled in the Beth Israel Deaconess Medical Center Lupus Cohort 2008-2022. The study was IRB approved. All patients met the 1997 ACR SLE criteria. Patients were categorized based on the presence and phenotype of LAD. Only patients in whom LAD could not be attributed to any other underlying cause were included. Demographic, clinical and laboratory parameters were compared between the groups. For statistical analysis x2 test for categorical variables and Student’s t-test for continuous variables were conducted using SPSS 27.

Results: 255 patients with SLE were included in the study, of whom 90 (35.29%) developed LAD; Lymphoma was the cause of LAD in three cases (3.33% of total LAD), one case was due to tuberculosis; these four subjects were excluded from this study. In total, 251 patients were included in the study (mean age 43.9±13 years, 92.8% female). 34.3% (86/251) of patients had at least one episode of LAD attributed to SLE. Patients with LAD had higher ACR/EULAR criteria score than patients who did not have lupus related LAD. Moreover, LAD was more common among black vs white patients (Table1). Clinical manifestations that presented significantly more frequently among patients with LAD included fever (40.7% vs 17%), weight loss (16.3% vs 5.5%), pericarditis (18.6% vs 6.1%), myocarditis (8.1% vs 0.6%), myositis (8.1% vs 1.8%), leukopenia (75.3% vs 55.6%), lymphopenia (78.8% vs 59.8%), and class V nephritis (18.6% vs 6.1%). Regarding serological markers, the presence of Smith Ab (61.9% vs 37.7%), RNP Ab (70.2% vs 47.9%), low C3 (80.2% vs 65.5%) and low C4 (70.9% vs 48.8%) were significantly more common in patients with LAD (Table 2). 38.4% (33/86) of the patients with LAD underwent lymph node biopsy, of which 66.7% (22) demonstrated a reactive/proliferative pattern and 33.3% (11) a necrotizing pattern (Figure1). When we compared the two phenotypes, we found that patients with necrotizing LAD were more likely to experience unexplained fevers, sicca and malar rash. No difference was identified regarding laboratory markers, the course or the extent of LAD between the two phenotypes. (Table 2).

Conclusion: In patients with SLE, the presence of LAD is common and associated with constitutional symptoms, myo/peri-carditis, cytopenias and nephritis, as well as with serological markers associated with increased disease activity. In this context, LAD may represent a manifestation of more active disease or an underlying process during the disease course. When comparing necrotizing vs reactive LAD, the presence of necrotic pattern in histology was associated with fever, malar rash, sicca but not worse prognosis. Lastly, in our cohort lymphoma was a rare but not infinitesimal cause of LAD (3.33% of LAD), pointing to the fact that although LAD is a common manifestation of SLE, biopsy is oftentimes needed to differentiate the two.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: E. Papachristodoulou, None; D. Magliulo, None; V. Kyttaris, Exagen, Corbus Pharmaceuticals, Aurinia Pharmaceuticals, Scipher.

To cite this abstract in AMA style:

Papachristodoulou E, Magliulo D, Kyttaris V. Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/lymphadenopathy-in-systemic-lupus-erythematosus-clinical-characteristics-and-prognostic-features/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lymphadenopathy-in-systemic-lupus-erythematosus-clinical-characteristics-and-prognostic-features/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology